Lungpacer Medical wins FDA premarket approval for AeroPace neurostim system
December 6, 2024
Lungpacer Medical announced that it received FDA premarket approval for its flagship AeroPace neurostimulation system.
Lungpacer Medical announced that it received FDA premarket approval for its flagship AeroPace neurostimulation system.
The solution offers clinical laboratories and healthcare providers a user-friendly, reliable, and cost-effective way to improve urine specimen collection, preservation, and transport.
LINKÖPING, Sweden, Dec. 6, 2024 /PRNewswire/ — SyntheticMR, leader in quantitative imaging software, is pleased to announce that its SyMRI 15 solution has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) on diagnostic image replacement of conventional images.
Field Medical announced today that it received FDA breakthrough device designation for its FieldForce pulsed field ablation (PFA) system.
A new medical innovation, developed in the UK by Europlaz, has the potential to help improve neonatal care and save the lives of more babies born prematurely or in distress according to the company.
MILPITAS, Calif., Dec. 5, 2024 /PRNewswire/ — LifeSignals, Inc. today announced that the UbiqVue 2A Multiparameter System has received EU MDR Certification, marking another significant milestone in deploying continuous wireless patient monitoring for population health management following FDA 510(k) Clearance last month.
First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT).
Implantable device works like a tree branch to grab and fling proteins
CLEVELAND, Dec. 4, 2024 /PRNewswire/ — Centerline Biomedical, Inc. (“Centerline”), an innovative leader in cardiovascular navigation and visualization systems, announced that the company has received US Food and Drug Administration (FDA) 510(k) clearance for its new IOPS Guidewire Handle
ShiraTronics announced that it initiated its FDA investigational device exemption (IDE) pivotal trial for its neuromodulation therapy.